Michael Hufford, PhD

Dr. Hufford is a biotech entrepreneur with a knack for tackling big public health challenges—he’s best known for co-founding Harm Reduction Therapeutics, working to make opioid overdose reversal meds more accessible.

Michael Hufford, PhD, is the Co-Founder and CEO of LyGenesis—a clinical-stage biotechnology company developing allogeneic cell therapies to enable organ regeneration. He has more than 20 years of experience obtaining FDA approvals and leading translational research, regulatory strategy and clinical development across biotech and pharma. Dr. Hufford’s philanthropic work includes co-founding Harm Reduction Therapeutics, a 501(c)(3) nonprofit pharmaceutical company that developed and commercialized RiVive®, a low-cost over-the-counter naloxone nasal spray to help prevent opioid overdose deaths.